Background: NOG gene is required for accumulation of mature osteoclasts and proper skeletal development. Results: NOG mediates breast cancer metastatic bone colonization by osteoclast differentiation and self-renewal metastatic properties. Conclusion: Expression of NOG in breast metastatic cancer cells provides them with bone colonization capabilities. Significance: The interplay of bone microenvironment and cancer cell autonomous functions define the selection of genes that lead to bone metastasis development.
cytokine-cytokine receptor interaction in predicting relapse, which highlights the importance of communication signals within cell types present in the tumor or at the metastasis site (5) . Examples of the biological significance of this analysis are TGFβ and BMP signaling pathways (5) . Perturbations of these signaling pathway are central to tumorigenesis and tumor progression in a cancer cell dependent and independent manner (6) .
Bone metastasis is a common site of breast cancer metastasis, being bone breakdown one of the most remarkable clinical features and the major source of morbidity associated with bone metastasis. Breast cancer bone metastases have been predominantly associated with an osteolytic phenotype due to the concerted collaboration between malignant cells and osteoclasts (7) . The bone microenvironment is comprised of osteoblasts, osteoclast, mineralized bone matrix, and other cell types embedded within the bone (8) . The crosstalk between tumor cells and the microenvironment has been suggested to fuel a "vicious cycle" of tumor growth and bone remodeling (9) , which relies on factors secreted by tumor cells that stimulate osteoblast and osteoclast proliferation and maturation leading to a net increase in osteoclast-mediated bone destruction. Osteoblasts produce and release the receptor activator of nuclear factor-kB (NFkB) ligand (RANKL), which binds to its receptor (RANK) displayed by osteoclasts precursors to induce the latter to mature into functional osteoclasts. The osteoblasts may also secret ostoprotegerin (OPG), which acts as a decoy receptor to ambush RANKL, and OPG determines the net rate of bone growth/loss. The Bone Morphogenic proteins (BMPs) are a family of growth factors that stimulate bone formation by shifting the equilibrium between OPG and RANKL to an accumulation of OPG (8) . NOGGIN, a BMP antagonist encoded by NOG, might shift the equilibrium in the opposite direction, leading to an accumulation of mature osteoclasts (8) . BMPs are multi-functional growth factors that belong to the TGFβ superfamily. BMPs were originally isolated by their ability to induce ectopic bone and cartilage formation in vivo (10) , but also act as multifunctional regulators in morphogenesis during development (10, 11) . In bone biology, BMPs have a crucial role in determining the body axis, bone and cartilage formation in embryonic development, postnatal bone metabolism and fracture healing (12) .
Who produces and how is TGFβ/BMP sensed by stroma and metastatic cells is a matter of great interest. Among the different players that could modulate TGFβ/BMP signaling pathway and its contribution we focused on NOG, a key player in bone metastasis given its action on bone remodeling processes as well as defining the stroma capacity to maintain cancer stem cells and their niche (13, 14) . NOG function antagonizes BMPs and is required for neural tissue formation, notochord, and early gastrulation stages (15) . NOG knockout shows NOG essential function in proper skeletal development (16) , suggesting its potential role and contribution in triggering bone remodeling functions, yet its functional role in breast cancer has not been evaluated. Here we report experimental and clinical data indicating that, NOG is in its own right a powerful double asset for breast cancer metastatic cells to the bone, a provider of stemness and metastatic niche specific capabilities.
EXPERIMENTAL PROCEDURES
Cell lines-The SKBr3, MCF7, MDA 231 and T47D breast cancer cell line were obtained from ATCC. The 1833 and the MCF7 BMd are bone metastatic sublines derived from MDA-231 (17) and MCF7, respectively. These cell lines and their genetically modified variants were maintained in 5% CO2 at 37º in DMEM medium (Gibco) supplemented with 10 % fetal bovine serum (Biological Industries), 100 U/ml of penicillin, 0.1mg/ml of streptomycin and 0.29 mg/nl of Glutamine. 293T cells, a lentivirus and retrovirus by guest on September 16, 2017 http://www.jbc.org/ Downloaded from packaging cell line, was maintained in DMEM supplemented with 10% FBS, 100 U/ml penicillin, 0.1 mg/ml of streptomycin and 0.29 mg/ml of glutamine.
Generation
of knockdown and overexpressing cells-Stable cell lines expressing the shRNA targeting NOG or a non-silencing shRNA were generated after lentiviral infection. The 293T cells were transfected with packaging vectors and shRNA carrying vectors (pLKO, from Sigma-Aldrich Mission shRNA library), supernatant containing virus was collected 48 h afterwards and used for infection of breast cancer cell lines. Infection was done for 24 h in presence of 8ug/ml of polybrene. Cells were recovered with fresh media and selected for 48 h with 4ug/ml of puromycin. Sequence for shRNA NOG: CCGGGCTAGAGTTCTCCGAGGGCTTC TCGAGAAGCCCTCGGAGAACTCTAGC TTTTTG For NOG overexpression in SKBr3 cells, NOG was cloned into the retroviral vector pBabePuro. As a control, pBabePuro empty vector was used. Retroviral virus was obtained by transfecting 293T cells and infection was done as described above. After infection, cells were selected with 4ug/ml puromycin during 48h. The rescue was done by generating a mutant vector (using multisite directed mutagenesis quick change kit (Stratagene) that had synonymous mutation in NOG open reading frame and was insensitive to given shRNA against NOG. Hygromycin selection marker was used in the latter case.
Animal studies and xenografts-All animal work was approved by the institutional animal care and use committee of IRB Barcelona. BALB-c nude mice of 8-10 weeks of age were used for all studies. For intracardiac injections, 10 5 cells were resuspended in 0.1 ml of PBS and injected into the left cardiac ventricle of the mice, using 25G needle as previously described (17, 18) .
Prior to injection mice were anesthetized with ketamine (100mg/kg body weight) and xylazine (10mg/kg body weight) and immediately after injection of tumor cells, mice were imaged for luciferase activity expressed stably by the indicated cell lines using a TK-GFP-Luciferase construct described elsewhere (18) . Animals were followed once a week using bioluminescence imaging (IVIS Xenogen) to assess bioluminescent activity. For tail vein injection cells were treated as for intracardiac injection and inoculated in the lateral tail vein. Mice were imaged for luciferase activity immediately after injection and continued to be monitored weekly using IVIS imaging.
Kaplan-Meier survival and correlation
analysis-All statistical analysis was performed using Bioconductor. The patient information has been downloaded from GEO. Two sets of data were used (a cohort of breast cancer primary tumors GSE12276 and a cohort of metastatic samples from breast cancer patients GSE14020). For each set NOG expression has been standardized to z-scored to make measurements comparable. The prognostic effect of NOG to predict recurrence-free survival, measured as hazard ratio, was assessed using a multivariate Cox proportional hazards model adjusted by age, hospital of origin and TNM stage. We measured NOG expressionphenotypic (HR of bone recurrence) association using Kaplan Meier curves.
Quantitative real-time PCR-Total RNA from sub-confluent cells was collected and purified using the PureLink TM Mini Kit (Ambion) and reverse transcribed using High-Capacity cDNA reverse transcription kit (Applied Biosystems) following the manufactures instructions. Tumorspheres were collected and RNA was isolated using TRIZOL according to manufacture instructions. The final step of elution was done using Quiagen RNAEasy Mini Kit 74104 columns and reverse transcription was done as described above. Real-time PCR was performed using TaqMan Gene 4 cells per well were seeded in p60 tissue culture plates in triplicates. After 4h the media was changed in order to remove all the non-attached cells and the concentration at this time point was determined using a cell counter (day 0). Cells were counted at day 1, 3, 5 and 7 and the results were normalized to day 0.
Osteoclast differentiation assay-In order to isolate bone marrow mononuclear cells, 4-6 week old wild type C57BL/6 mice were sacrificed and their femur and tibias were flashed with cold PBS solution and bone marrow mesenchymal cells were cultured in 100mm dishes overnight in α -MEM (Invitrogen) media supplemented with 10% fetal bovine serum, 100 U/ml penicillin, 0.1 mg/ml of streptomycin and 0.29 mg/ml of glutamine. After overnight culturing, nonadherent cells were collected and plated in the same media. After 2 days the adherent cells were scraped and counted in order to be plated in 24 well dishes and osteoclast differentiation was induced by adding the 20ng/ml RANKL (peproTech), 30ng/ml M-CSF (R&D Systems) and conditional media from breast cancer cells. Medium was changed at day 3 and TRAP staining (Sigma-Aldrich) was performed at day 6. Differentiated multinucleated (>3 nuclei) osteoclasts were stained by TRAP staining. Quantification of TRAP+ cells was performed and the average of three independent experiments was plotted with SD values.
Tumorspheres formation assay-In order to assess the tumor initiation capability in vitro, cells were counted and plated into low attachment 96-well plates at dilution of 1 cell per well and cultured in tumorspheres media (MEBM media with all supplement and with 20 ng/ml of basic FGF and 2 % B27 supplement). Process was repeated to ensure second-generation tumorspheres. After two weeks of culturing the tumorspheres were counted under the microscope. CT-scan analysis-Development of bone metastasis was monitor by CT imaging (CTSkyScan). Visible metastatic lesson were measured using Image J software and osteolytic area was calculated in mm 2 .
Migration and invasion assay-

RESULTS
Selection of NOG expression in bone metastatic breast cancer cells-
We used a panel of well-defined breast cancer cell lines (ATCC) originated from patient breast cancer metastasis or primary tumors to evaluate NOG expression in breast cancer cells. We correlated the levels of NOG expression in those cells with its capacity to form bone metastasis when intracardiacally inoculated in immunocompromised BALB-c nude mice. NOG mRNA was detectable in all cell lines. However, the levels varied enormously between them ( Figure 1A ). Among them, the ER-negative MDA-231 and 1833 cells had the highest level of NOG expression ( Figure 1A ), being the 1833 a bone metastatic cell line derived from the MDA-231 cells (17) . A similar increase of NOG expression was observed in the ERpositive MCF7 cells that grew at the bones, MCF7 BMd. Cell lines with the higher levels of NOG coincide with those with the highest capacity to form bone metastasis ( Figure 1B ). On the contrary, cell lines expressing low levels of NOG were not associated with bone metastasis, as is the case of SKBr3 and T47D cells ( Figure 1A and 1B). Thus, suggesting that NOG expression might be necessary but not sufficient since other cell-autonomous requirements have been shown to be necessary to colonize the bone (2). Of note, this association occurred independently of metastasis to soft tissues (Supplemental Figure 1 ).
NOG Expression is Associated with Bone
Metastasis in patients-Given the striking association between NOG expression and the breast cancer cells capacity to take and metastasize to the bone, we decided to evaluate to what extent NOG levels could predict relapse to the bone in primary breast cancers. Thus, we hypothesized that selection of NOG expression in the primary site would endow tumor cells with the ability to efficiently seed the bones, suggesting NOG could be a metastasis progression or initiation gene (4) . In breast cancer primary tumors (cohort GSE12276; n=198 including tumors that did relapse to the bone, brain and lung and tumors that did not relapse), NOG mRNA expression levels were not associated with a high probability of relapse to the bone in the patients ( Figure  2A ), indicating that NOG does not predict bone relapse from the primary site. However, when we focus on metastatic samples originated in patients with a previous episode of breast cancer (GSE 14020, (19) ), NOG levels were upregulated in bone metastatic lesions as oppose to brain, lung and liver lesions ( Figure 2B ). The data reflects a trend of high NOG expression in bone metastasis cohort (n=27). Collectively, these results suggest that bone specific breast cancer metastatic cells select or arise from a population with high NOG expression.
NOG promotes experimental bone metastasis in vivo-Given the bioinformatics observation of NOG expression in organspecific metastasis to bone, we thus decided to evaluate the role of NOG in a breast cancer bone metastasis experimental model. To this end, we performed experimental bone metastasis assays in nude mice using the 1833 bone metastatic cell line. An 1833 cell line derivative with a knockdown using a shRNA targeting NOG (NOG-KD, 70% reduction of NOGGIN protein levels) was used along with cells rescued with a NOG mutated form resistant to the shRNA effects and control cells ( Figure 3A and B) . Changes in the levels of NOG did not result in consistent changes in the BMP-2, -3, -4, -6 or -7 expression levels (Supplemental Figure 2) . Following intracardiac injections of tumor cells prelabeled with a luciferaseexpressing construct, metastatic progression in the bones was followed via quantitative bioluminescence imaging over the course of 8 weeks. NOG-KD cells had dramatically reduced the probability to form bone metastasis as well as reduced metastatic burden at 1-week post injection, and these differences were maintained throughout the experiment ( Figure 3 C and D) . 1833-NOG-KD cells showed a dramatic reduction (>10 fold) in metastatic burden that was significant (p<0.05, Man-whitney U test) and was restored upon re-introduction of a mutant NOG form resistant to shRNA ( Figure 3D ). These results highlight that the magnitude of the loss of metastasis phenotype correlated with the efficiency to specifically knockdown NOG. To test whether NOG expression could affect bone metastasis in a different cell line that express low levels of NOG and shows a clear inability to colonize the bones, experimental metastasis assays were repeated in SKBr3 cells, which ineffectively colonize the bone albeit they are very aggressive in in vitro models (20) . Here again, high levels of NOG, 9-fold increase in NOGGIN protein levels, led to a significant increase in the probability to develop bone metastasis and to a dramatic increase in metastatic burden through the course of the 9 weeks experiment (>10-fold: p<0.05, Mannwhitney U test) ( Figure 3 E and F) .
To test whether NOG-KD or overexpression affected metastasis elsewhere, control and knockdown 1833 cells and control and overexpressing SKBr3 cells were injected via tail vein of nude mice. We monitored the kinetics of emergence of lung colonization by real-time quantitative bioluminescence imaging of luciferase activity from a stably integrated vector. Neither the control nor NOG-KD 1833 cells, bone metastatic MDA-231 derivative, were able to colonize the lung 60 days after injection as previously observed for control cells (Data not shown) (21) . Similarly, neither SKBr3 nor SKBr3-overexpressing NOG displayed any capacity to colonize the lungs ( Figure 3G ). Figure 1 ). Besides this possible role on proliferation and invasion, we next investigated the role of NOG in apoptosis in vitro with no results (data not shown). Yet, to rule out the lack of any phenotype due to the use of an in vitro experimental approach, we verified in bone metastatic lesions derived from cells expressing different levels of NOG that no significant changes in proliferation (Ki-67 nuclear staining) or apoptosis (Cleaved Caspase-3 staining) were accounting for the differences observed ( Figure 4A ).
NOG functions to support breast cancer osteolytic lesions in the bone-
Given NOGGIN is a BMP inhibitor, and BMPs signaling defines the balance between differentiation of bone marrow derive cells to osteoclast or osteoblasts (8), we investigated the contribution of NOG in the formation of osteolytic/osteoblastic lesions. We confirmed in metastatic lesions from 1833 and SKBR3 parental cells that BMP signaling, determined by means of P-SMAD1/5/8, was active on bone marrow stromal cells (Supplemental Figure 3) . To test whether NOG produced endogenously or exogenously by 1833 or SKBr3 metastatic cells could be playing a role in bone remodeling processes, we assessed metastatic burden and bone structure via Figure  4B and C) . Moreover, the CTscan analysis depicted osteolytic metastatic lesions in mice inoculated with breast cancer cells expressing high levels of NOG ( Figure 4B and C). Differences in the osteolytic area were clearly observed in the 1833 cells experimental setting given the highly bone metastatic aggressiveness of these cells. We found that silencing of NOG led to a significant 2-fold decrease in osteolytic bone metastatic area compared with control and rescued 1833 cells ( Figure  4B ). Quantification of osteolytic bone metastasis area was in agreement with the photon flux results ( Figure 3D ).
To identify the potential effectors of NOG mediated breast cancer osteolytic bone metastasis phenotypes, we assessed the capacity of breast cancer metastatic cells to trigger osteoclast differentiation at the perimeter of bone metastatic lesions in vivo.
Osteoclasts are large multinucleated cells found in the bone, whose function is to break down and digest the bone when activated, as opposed to osteoblasts whose function serves the purpose of bone synthesis. Histological analysis of sizematched tumors showed a decrease in the number of tartrate-resistant acid phosphatase-positive (TRAP+) osteoclasts along the bone-metastatic tumor interface, in bone lesions generated by NOG-KD cells, when compared to the controls or Rescue 1833 cells (control and rescue 16.6%±3.0, sh NOG 9.9%±3.0; Figure 5A ). To confirm NOG-driven osteoclast differentiation in breast cancer bone metastatic lesions, we quantified TRAP+ cells in Control and NOG-overexpressing size match SKBr3 cell bone metastasis revealing a more than 50% enrichment of osteclasts/perimeter when lesions are formed by NOG-expressing cells (SKBr3 control 14.1%±3.1, SKBr3 NOG 22.8%±0.4; Figure 5A ). To confirm more rigorously the positive stimulation of osteoclast differentiation by metastatic cells NOG-expression, we performed in vitro osteoclast differentiation assay. The assay consisted in growing primary bone marrow derived cells from C57BL/6 mice in media containing 1:1 ratio of conditioned media collected from control-and NOG-KD 1833 or control and NOG-expressing cells and α-MEM media supplemented with macrophage colony stimulating factor (M-CSF) and RANKL. M-CSF induces the differentiation of murine bone marraw cells into macrophages and RANKL is an essential cytokine for osteoclastogenesis. Under these conditions, a reduction in Phospho-SMAD1/5/8 levels, used as a surrogate of BMP signaling activity, in bone marrow cells was detected when conditioned media of 1833 NOG expressing cells was used, which was reverted upon NOG-KD or when media not pre-incubated with 1833 cells was used ( Figure 5B ). Seven days post initiation of osteoclasts differentiation protocol, TRAP+ multinucleated (>3 nuclei) mature osteoclasts were scored ( Figure 5B ). Treatment with conditioned media derived from cells expressing high levels of NOG (1833 and SKBr3-NOG) resulted in a 5-fold increase in the number of osteoclasts compared to NOG-KD 1833 or SKBr3 cells ( Figure 5C ). No differences in RANKL expression were observed in breast cancer cells upon changes in NOG expression that could contribute to in vitro osteoclast differentiation (Supplemental Figure 4) . These results suggest that NOGGIN released by cancer cells is a key player in the metastasis cell-stroma interaction at the bone, which could explain why metastatic cells to the bone but not other tissues select for NOG expression.
NOG expression contributes to metastatic reinitation at the bone-BMPs have been
shown to prevent stem cell renewal of the neural crest and intestinal epithelia stem cells (22 Figure 3) , and overexpression of NOG clearly blunted BMP2 activity (Supplemental Figure 3) . We did not observe significant and consistent differences in migration or invasion upon changes in NOG expression (Supplemental Figure 5) .
To further validate our hypothesis, we analyzed the ability of the different NOG-expressing cell derivatives to form second-generation tumorspheres. We observed that the 1833 cells form tumorspheres per se in high propensity ( Figure 6A ), but when NOG was downregulated these ability was reduced by 80% ( Figure 6A ). Conversely, when SKBr3 cells undergo the same test, we observed that only 10% of the single cells were able to form tumorspheres, but this was dramatically increased up to 40% upon NOG expression ( Figure 6A ). Interestingly, NOG levels also defined the shape of the tumorspheres ( Figure 6A ). Next, we aimed to address the mechanistic contribution of NOG to the reinitiation process. We measured in tumorspheres the expression levels of ID1 and ID2, two well-known targets of the BMP pathway that contribute to cell growth, senescence, and negatively regulating differentiation (22) , and we also measure the levels of RANK, recently described to be key in the expansion of the mammary stem cell compartment in normal breast epithelial and in cancer (23, 24) and upstream of ID2 (25) . There was no significant difference in ID1 levels between groups, while the levels of ID2 and RANK changed accordingly to NOG levels ( Figure  6B and C) . Taken together, these data suggest that NOG selection in breast cancer metastatic cells to bone is relevant, providing reinitiation and, particularly, bone metastatic capabilities.
DISCUSSION
NOG has generated high levels of interest in recent years as it has been shown to promote experimental bone metastasis. To date, investigations of how NOG promotes such phenotypes have generally focused on osteolytic lesions in the context of prostate cancer (26, 27) . However, comparatively prostate cancer renders osteoblastic lesions (8) while osteolytic lesions are largely associated with bone metastasis in breast cancer. Prostate and mammary cancer bone metastases can be osteoblastic or osteolytic, but the mechanisms determining these features are unclear. Bone morphogenetic and Wnt proteins are osteoinductive molecules (28) . In prostate, their activity could be modulated by antagonists such as NOGGIN and DICKKOPF-1 (29) . Sonic Hedgehog signaling pathway was shown to augment BMP7 and NOGGIN and to accelerate tumor growth in prostate xenograft (30) . This "bone-homing function" was suggested to mediate the interaction between prostate cells and bone stroma. However, the putative contribution of NOG in breast cancer has not yet been identified. Here we identified NOG to be upregulated in breast cancer cells with specific capacity to form bone metastasis in experimental models. Our current study provides evidence to link NOG expression selection in bone but not lung, brain or liver metastasis in breast cancer patients irrespectively of NOG expression in breast cancer primary tumors. The specificity of bone selection for the expression of NOG led us to hypothesize that NOG provides a key tissue specific colonization function that makes it unique of bone metastasis.
NOG gene encodes a secreted polypeptide called NOGGIN. NOGGIN is a BMPspecific antagonist protein found to rescue dorsal (head) structures in ventralized Xenopus embryo (31 (7, (32) (33) (34) . BMP signaling has been shown to be determinant for the balance between osteoclast/osteoblast differentiation processes by triggering osteoblast differentiation (8) . Collectively, we propose an indirect mechanism by which an excess of NOG produced by tumor cells might alter the osteoblasts capacity to sense BMP, favoring an excess of osteoclasts and a more osteolytic phenotype of bone metastatic lesions. Moreover, we have shown that NOG is a driver of this effect, since the activation was observed in the presence of NOG and it was lost when NOG was depleted. Previous studies have shown that conditioned media of MDA-231 breast cancer cells induce osteoblast apoptosis in vitro (35, 36) , which under certain circumstances might add on the NOG phenotype described herein.
Not all the cells that get to the metastasis site have the capacity to reinitiate the tumor growth, but only a few of them will be able to reinitiate a lesion (37) . These cells have been described as putative breast cancer stem cells. NOG as an antagonist of the BMP pathway, a pathway that has been shown to induce the differentiation of cells (38) , has been suggested to play a determinant role preventing the differentiation process elsewhere (22) . Moreover, NOG has been previously related with the increase of the colon stem epithelial compartment by disabling BMP signaling repression on de novo crypt formation (39) . Breast cancer stem cells can be isolated using: 1) non-adherent culture conditions to form tumorspheres and 2) identifying the cells by their surface expression of CD24 and CD44 (37) . Our results showed that cells expressing high levels of NOG are selected for cancer stem cells, since they formed more tumorspheres and resulted in higher numbers of CD24 low CD44 high (data not shown). Indeed, the ability to form tumorspheres was in agreement with the ability of these cells to metastasize into the bone. Moreover, we checked the expression levels of the differentiation regulators ID1 and ID2 in the tumorspheres. No significant difference of ID1 expression was observed among the different groups of tumorspheres. However, ID2 expression levels were increased in tumorspheres of SKBr3-NOG overexpressing cells. In agreement with this observation, ID2 was downregulated when NOG was depleted in the 1833 cells. Moreover, the induction of ID2 correlated with a higher expression level of RANK, which has been described to be key to maintain the pool of mammary stem epithelial cells (24) and is in agreement with previous findings (25) . Previous publications have shown that RANKL is responsible of the epithelial cells proliferation in response to progesterone (40) , and is the main mediator of the protumorigenic role of progesterone in the mammary gland (23, 41) . The luminal cells release RANKL, which binds to the RANK exposed by mammary stem cells (MaSCs) and therefore stimulates the self renewal process of these cells (42) . These results suggested NOG as a modulator of breast cancer reinitiation through ID2 and, subsequently, altering the levels of RANK or the other way around. Finally, the expression of high levels of RANK has been by guest on September 16, 2017 http://www.jbc.org/ Downloaded from linked to resistance to chemotherapy (23) , which might open the possibility that metastatic cells expressing high levels of NOG are resistant to therapeutic regime in metastatic patients. We interpret the influence of NOG into the ability to successfully metastasize indicating that metastatic cells acquire the ability to home and breach the environment of the bone, but also to endow metastatic cells with metastatic self renewal activities. Thus, the latter process is likely to take place in a tissue independent manner, as the ability of breast cancer cells to reinitiate a lesion might be independent of the metastatic site.
However, if RANK mediated the selfrenewal activity the further requirement for its stimuli, RANKL, driven by the bone environment might explain why no effect on the primary or other metastatic sites is observed. Collectively, our results suggest that breast cancer bone metastasis cells select for NOG expression when metastasize the bone since its acquisition provides the disseminated cells functions to specifically home, seed, reinitiate and colonize the bone, by enhancing self-renewal functions as well as by altering the bone microenvironment favoring the activation of osteoclasts. 
